Unknown

Dataset Information

0

Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy.


ABSTRACT: OBJECTIVE:The primary aim was to determine the safety of treatment with human immune globulin 10% with recombinant human hyaluronidase (fSCIg) compared to intravenous immunoglobulin (IVIg) in a prospective open-label study in patients with multifocal motor neuropathy (MMN). METHODS:Our study consisted of two phases: the IVIg phase (visits 1-3; 12 weeks), in which patients remained on IVIg treatment, and the fSCIg phase (visits 4-7; 36 weeks), in which patients received fSCIg treatment. After visit 3, IVIg was switched to an equivalent dose and frequency of fSCIg. Outcome measures were safety, muscle strength, disability and treatment satisfaction. RESULTS:Eighteen patients were enrolled in this study. Switching to fSCIg reduced the number of systemic adverse events (IVIg 11.6 vs. fSCIg 5.0 adverse events/per person-year, p?

SUBMITTER: Herraets IJT 

PROVIDER: S-EPMC6803588 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy.

Herraets Ingrid J T IJT   Bakers Jaap N E JNE   van Eijk Ruben P A RPA   Goedee H Stephan HS   van der Pol W Ludo WL   van den Berg Leonard H LH  

Journal of neurology 20190719 11


<h4>Objective</h4>The primary aim was to determine the safety of treatment with human immune globulin 10% with recombinant human hyaluronidase (fSCIg) compared to intravenous immunoglobulin (IVIg) in a prospective open-label study in patients with multifocal motor neuropathy (MMN).<h4>Methods</h4>Our study consisted of two phases: the IVIg phase (visits 1-3; 12 weeks), in which patients remained on IVIg treatment, and the fSCIg phase (visits 4-7; 36 weeks), in which patients received fSCIg treat  ...[more]

Similar Datasets

| S-EPMC4098937 | biostudies-literature
| S-EPMC6353406 | biostudies-literature
2018-10-22 | PXD008014 | Pride
| S-EPMC3896049 | biostudies-literature
| S-EPMC9300115 | biostudies-literature
| S-EPMC4621010 | biostudies-literature
| S-EPMC4484896 | biostudies-literature
| S-EPMC6794440 | biostudies-literature
| S-EPMC7473831 | biostudies-literature
| S-EPMC8247955 | biostudies-literature